Clearside Biomedical Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Clearside Biomedical Inc 's ROA in the third quarter of 2025?
Clearside Biomedical Inc recorded a cumulative net loss of $-26 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -144.9%.

However, within the Healthcare sector 823 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4502, from total ROA ranking in the second quarter of 2025 at 4529.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-60.08 %	-54.82 %	-51 %	-26.14 %	-15.28 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-26	-28	-31	-34	-32
Return On Assets (TTM)	-144.9 %	-124.15 %	-114.24 %	-107.05 %	-92.9 %
CLSD's Total Ranking	# 4502	# 4529	# 4579	# 5252	# 4576
Total Assets (TTM) in million	12	15	20	25	29
Seq. Total Assets Change	-24.07 %	-22.05 %	-21.72 %	-13.84 %	-14.07 %
Seq. Net Income Change	-	-	-	-	-

CLSD's 5 Years Annual ROA >> Back to CLSD Management Effectiveness >> Compare CLSD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 389
Sector	# 824
Overall	# 4449

Return On Assets Statistics
High	Average	Low
1.19 %	-81.24 %	-147.38 %
(Dec 31 2021)		(Jun 30 2019)

Financial Statements
Clearside Biomedical Inc 's Assets	$ 12 million	CLSD's Balance sheet
Clearside Biomedical Inc 's Income	$ -6 million	Quarterly CLSD's Income Statement
CLSD's Income by Division		See CLSD's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-26.14 %	-32.26 %	18.06 %	126.32 %	-28.05 %
Total Assets in million	25	34	50	43	19
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-34	-32	-33	0	-18
Annual Return On Assets	-136.72 %	-95.49 %	-65.61 %	0.88 %	-96.89 %

CLSD's 5 Years Annual ROA >> Back to CLSD Management Effectiveness >> Compare CLSD ROA to its Competitors

More Return On Assets Ratios
CLSD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CLSD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CLSD's Competitors
Subscribers only: Roa for Clearside Biomedical Inc 's Suppliers
Subscribers only: Return On Assets for CLSD's Customers

You may also want to know
CLSD's Roi	CLSD's Inventory Turnover Ratio	CLSD's Growth Rates	CLSD's Dividend Comparisons
	CLSD's Profitability Ratios	CLSD's Asset Turnover Ratio	CLSD's Dividend Growth
CLSD's Roe	CLSD's Valuation Ratios	CLSD's Financial Strength Ratios	CLSD's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:29:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.